Outcome of Second Allogeneic Stem Cell Transplantation (SCT) in Pediatric Patients With Graft Failure or Recurrent Leukemia  by Pawlowska, A.B. et al.
Poster Session II S309than 1000/microlitter following conditioning. Considering platelets,
157 and 12 of patients did not have platelet count less than 20,000
and 100,000/mcrolitter after transplantation respectively. There
was no difference for engraftement days between ABO mismatched
and matched group. The median RBC transfusion requirement
was 7 units prior to 100 days post-HCT and 8 units through one
year post-HCT and overall follow-up across all recipients.
Table 1. RBC transfusions in ABO major/bidirectional mis-
matched and matched donor-recipient pairs.
Major/bidirectional
All patients missmatch Match P-Valueat 100 days 7.5 8 6 0.11
at 1 year 8 10 8 0.071
overall 8 11 8 0.043A significantly higher total number of RBC transfusions occurred in
major and bidirectional ABO mismatches compared to ABO
matched transplants (11 units vs 8 units; p5 0.043); however, trans-
fusional requirements were only modestly increased throughout the
first year following transplantation in major/bidirectional mismatch
group (10 units vs. 8 units; p 5 0.061). The increase in overall RBC
transfusion was not associated with differences in rates of GVHD,
disease relapse, or overall survival.
Conclusion:ABOmismatchmay be associated with an increased re-
quirement for RBC transfusion after TLI/ATG conditioining.Man-
agement strategies for excessive RBC transfusion after ABO major
mismatched HCT require further study but may target persistent
recipient plasma cells secreting anti donor ABO antibodies.427
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Both graft failure or leukemia relapse after an allogeneic SCT are
associated with high mortality rate and available treatment options
are limited. We report 22 patients (age 3.9-19.7 years) with hemato-
logical malignancies who received second allogeneic SCT at COH
from 4/2000 – 12/2009 for graft failure (8 patients: AML–3 patients,
ALL-3 patients, CML-1 patient, Lymphoma-1 patient) or recurrent
leukemia (ALL-5 patients, AML-9 patients). Reduced intensity reg-
imen was used in 18 patients; only 4 received myeloablative condi-
tioning. 9 (41%) patients received transplants from the same
donor, and in13 (59%) a different donor was used. Half of the pa-
tients (11) received the second SCT within a year of the first SCT
(median: 391 days, range: 44-1,715). Overall survival for the whole
group at 100 days and 2 years were 77% (60-88%), 45% (35-
55%), respectively. The median follow-up for the 8 (36%) surviving
patients was 4.5 years (range: 0.5-10.6). Patients with graft failure
had superior overall survival (75% at 2 years) compared with recur-
rent disease (28%, p5 0.04) Less advanced disease status (1CR/2CR
vs 3CR/active disease) and diagnosis of non-ALL were associated
with higher likelihood of survival (p 5 0.02, p 5 0.02, respectively).
Survival for patients with less than one year between transplants
(31% at 2 years) did not differ from those receiving the second
SCT later than one year (60%, p 5 0.81). Within 100 days post
transplant 3 patients were diagnosed with CMV, 3 patients with
other viral infection (adeno, VZV, HSV), 12 patients had 23 culture
proven episodes of bacterial infections, 5 patients developed Clos-
tridium difficile enterocolitis and 1 patient was diagnosed with As-
pergillus fumigatus. In summary, second SCT used for graft
failure or leukemia relapse in pediatric patients with hematological
malignancies is associated with acceptable transplant related toxicity
and infection rates. For patients with graft failure the long term out-
come is excellent; for patients with relapsed leukemia second trans-
plant should be offered as a treatment option as it can lead to long
term disease free survival.428
ELEVATED PRE TRANSPLANT SERUM FERRITIN IS ASSOCIATEDWITH IN-
CREASED RISK OF INVASIVE MOLD INFECTION (IMI) AFTER ALLOGENEIC
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Elevated pre transplant serum ferritin, a measure of iron overload
is associated with various adverse outcomes after allogeneic HSCT
including increased risk of fungal infections. Invasivemold infections
(IMI) are life threatening complications after allogeneic HSCT and
are mostly caused byAspergillus species and Zygomycetes. Small case
series have shown elevated iron stores in HSCT patients who devel-
oped IMI. We examined if elevated serum ferritin prior to HSCT
was associated with increased risk of IMI after allogeneicHSCT. Pa-
tients who underwent allogeneic HSCT from March 2005 through
December 2009, in whom a pretransplant ferritin level was available,
are included in this analysis. Serum ferritin was measured upon ad-
mission for HSCT prior to initiation of conditioning regimen.
Proven or probable IMI was diagnosed according to EORTCMyco-
sis Study Group criteria. Elevated serum ferritin was defined as
values above 1000 ng/ml. Pretransplant ferritin levels were available
in 478 patients. 9 patients (1.9%) had developed IMI at day 30 and 21
patients (4.4%) had IMI at day 100. Among the high ferritin group, 8
of 220 patients developed an IMI within 30 days after HSCT com-
pared to 1 of 258 patients in the low ferritin group (P 5 0.01). 14
of 220 and 7 of 258 patients in the high and low ferritin groups re-
spectively had developed an IMI by day 100 after HSCT (P 5
0.043). The median ferritin level in patents who had IMI at day 30
was 1810 ng/ml compared to 940 ng/ml in those who did not develop
IMI (P 5 0.006). For patients who developed IMI within 100 days
after HSCT, the median ferritin level was 1420 compared to 940
ng/ml for those who were free of IMI. Iron overload as measured
by pretransplant serum ferritin is associated with increased risk of
IMI after allogeneic HSCT. Fungal prophylactic strategies that
cover IMI are particularly important in iron overloaded recipients
of allogeneic HSCT.429
IN VIVO T-CELL DEPLETION (TCD) DOES NOT IMPROVE RATES OF
GRAFT-VERSUS-HOST DISEASE (GVHD) AND TRANSPLANTATION OUT-
COMES IN PATIENTS UNDERGOING PERIPHERAL BLOOD ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANT (AHCT)
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In vivoTCD is commonly employed to prevent graft rejection and
GVHD in patients undergoing AHCT. Published (but controver-
sial) data suggest possible benefit with TCD in the setting of unre-
lated donor (URD), and HLA-mismatched AHCT. We report
here outcomes for patients who received TCD with transplant
conditioning (TCD group) and compare them with patients who
received T-cell replete allografts (non-TCD group).
The study cohort consists of 150 consecutive patients who under-
went AHCT between 2003 and 2009. All patients received periph-
eral blood allografts. TCD consisted of alemtuzumab (20mg on
days -4 and -1; n5 39) or thymoglobulin 6 mg/kg (total dose) for ab-
lative and reduced intensity conditioning transplants and 7.5 mg/kg
(total dose) for non myeloablative allografts (n 5 51). 4 patients
received Atgam at 30mg/kg on days -5 to -3.
Patient characteristics of TCD and non-TCD groups are shown
in table 1. Significantly more patients in the TCD group had high
risk disease (86.3% v 61.8%, p\ 0.05) and received AHCT from
URD (62.1% v 29.1%, p\0.05). Median follow-up of surviving pa-
tients is 3yrs. There was no significant difference between engraft-
ment kinetics of two groups. The rates of acute GVHD II-IV in
the TCD and non-TCD groups were 42.1% (n 5 40) and 50.9%
(n 5 28) respectively (p0.32).On subgroup analysis rates of acute
GVHD II-IV in the TCD and non-TCDgroups for matched sibling
